Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.36 |
| ▸ | MLNR | O43193 | 2/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | GPR6 | P46095 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775982 | 0.86 | CACNA1G (0.43) | — | |
| SCHEMBL19670155 | 0.86 | HDAC2 (0.36) | HDAC2ROCK2SLC22A12MTORADORA2A | |
| SCHEMBL16775983 | 0.86 | HDAC2 (0.39) | HDAC2MLNRMTORADORA2AGSK3B | |
| SCHEMBL16775991 | 0.86 | THRB (0.39) | HDAC2MLNRMTORADORA2A | |
| SCHEMBL16775950 | 0.85 | SLC5A1 (0.40) | ROCK2KIT | |
| SCHEMBL16775980 | 0.84 | GRM5 (0.39) | MLNRMTORADORA2AGSK3B | |
| SCHEMBL16775952 | 0.83 | GPR65 (0.36) | HDAC2 | |
| SCHEMBL16775989 | 0.83 | RPS6KA3 (0.41) | MLNRMTORADORA2A | |
| SCHEMBL16775933 | 0.82 | USP30 (0.39) | MLNRMTORADORA2A | |
| SCHEMBL16775992 | 0.81 | GRM5 (0.40) | HDAC2MLNRMTORADORA2AGPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HDAC2 50/4885ROCK2 3343/4885MLNR 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.